Aptevo Therapeutics announced that two additional frontline Acute Myeloid Leukemia (AML) patients achieved remission within 30 days of treatment in the RAINIER dose optimization trial. This trial evaluates mipletamig in combination with standard of care for patients unfit for intensive chemotherapy. The consistent rapid remission rates highlight mipletamig's therapeutic potential.
Across two trials, a total of 9 out of 10 frontline patients achieved remission when treated with the triplet combination of mipletamig, venetoclax, and azacitidine (ven/aza). This triplet combination continues to outperform the doublet combination benchmark, demonstrating a compelling efficacy advantage. The data reinforces mipletamig's position as a differentiated immunotherapy.
Notably, no cytokine release syndrome (CRS) has been observed in the RAINIER trial to date, indicating a strong safety profile. This favorable safety aspect is critical for frontline AML patients, particularly those who are medically unfit. Cohort 2 enrollment is nearing completion, signaling continued progress in the trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.